Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions

NCT00650520 is registered in ClinicalTrials.gov with Mylan Pharmaceuticals Inc as lead sponsor.

NCT NCT00650520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00650520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Mylan Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets Following a 10 mg Dose in Healthy Adult Volunteers Under Fed Conditions
Lead sponsor
Mylan Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2007
Completion date
July 31, 2007
Enrollment
119 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy